Company Introduction

Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases

History

CELLID HISTORY
2022
  • Approval of phase 2b clinical trial for 'AdCLD-CoV19-1', COVID-19 prevention vaccine
2021
  •  Commencement of COVID-19 vaccine phase 2a clinical trial
  •  Selected by  Korea Drug Development Fund of the Ministry of Health and Welfare for COVID-19 preventive vaccine clinical support (Phase 1/2) 
  •  Commencement of COVID-19 vaccine phase 1 clinical trial
2020
  •  Approval of phase 1/2a clinical trial for COVID-19 prevention vaccine (December 4)
  •  Completion of Vaccine & Cell Genetic Treatment GMP Center
  •  Selected by the Ministry of Science and ICT for developing original technology of COVID-19 and variants prevention vaccine
  •  Completion of phase 1 clinical trial for BVAC-B
  •  Approval of Phase 1 clinical trial for BVAC-P
2019
  • Signed contract for Seongnam SK V1 tower (6F, Drug product)
  • Listed on the KOSDAQ market (February 20)
2018
  • Signed contract to move into Magok General Industrial Complex
  • Received 'Bio Awards', the 4th Korea Enterprise Awards hosted by Money Today
  •  Selected by the Ministry of Health and Welfare for  BVAC-C phase 2 clinical trial
  •  Approval of Phase 1 clinical trial for BVAC-B 
2017
  •  Approval of phase 2a clinical trial for BVAC-C
  • Selected by the Ministry of Trade, Industry and Energy for BVAC-B phase 1 clinical trial and BVAC-P non-clinical trial 
2016
  •  Completion of the development of original technology platform, CeliVax.
  •  Applied for CeliVax trademark
  •  Selected by the Ministry of Science and ICT for developing new convergence antigens
  •  Approval of BVAC-C phase 1 clinical trial of BVAC-C
  •  Selected by the Ministry of SMEs and Startups for BVAC-C phase 1 clinical development
2015
  • Selected by the Ministry of SMEs and Startups for BVAC-B development
2014
  •  Signed an agreement to license out BVAC-C
  •  Selected by the Ministry of Health and Welfare for BVAC-C non-clinical development
  •  Secured CeliVax patents
  •  Received certification of venture company
2007
  • Commencement of development of original technology platform, CeliVax
2006
  • Founded on 11 December